ERBB2 and neoplasm: This prosthetic group was reported with an anti-HER2 sdAb, offering similar tumor targeting as its randomly functionalized analogue with iso-[125I]SGMIB but with a 2-fold higher tumor-to-kidney ratio and a 3-fold higher tumor-to-liver ratio [81].